Corporate Profile  

Target Market 
 

Business Strategy
Our Story

Mission Statement

Officers & Key Personnel

Scientific Advisory Board

 

   
CVBT Scientific Advisory Board  
 

 

CVBT's research work is led by its Scientific Advisory Board. The Board consists of some of the world's leading scientists in the fields of protein biochemistry and angiogenesis:

Ralph A. Bradshaw, Ph.D.
Chair of Scientific Advisory Board

Vance Gardner, M.D.
Director of Orthopaedic Education and Research Institute of Southern California

John (Jack) William Jacobs, Ph.D.
Vice President, Chief Scientific Officer and Chief Operating Officer


Kenneth A. Thomas, Ph.D.
Vice President, Research and Development

Lynne Wagoner, M.D.
Cardiologist, Greater Cincinnati Cardiovascular Consultants (GCCC)

 

 

 


 

 

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.

 

2/24/2009
CVBT Opens Florida and Arizona Sites for Its ACORD Phase II Heart Trial


1/8/2009
CVBT Opens Two Additional Sites for Its ACORD Phase II Heart Trial


12/11/2008
CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial


11/25/2008
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease